Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
AstraZeneca
Colorcon
McKinsey
Medtronic

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LUTROPIN ALFA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Lutropin Alfa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00328926 LuverisĀ® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L]) Terminated EMD Serono Phase 4 2006-03-01 Sponsor has decided to discontinue LuverisĀ® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.
NCT00749853 Efficacy of Ovarian Stimulation Based on FSHR Genotype Status Suspended Medical University of Vienna Phase 3 2015-05-01 Available data from in vitro studies and clinical trials indicate that genetic factors play a significant role in the success of controlled ovarian stimulation (COS) prior to in vitro fertilization - embryo trandfer (IVF-ET). Women with the FSHR Ser680Asn Ser/Ser genotype make up between 13% and 26% of women undergoing IVF-ET and are characterised by higher basal FSH serum concentrations, the need for a higher amount of FSH for COS, and a higher risk of poor response to COS and cycle cancellation. The investigators therefore intend to perform a study to investigate whether a dose-intensified COS protocol based on FSHR genotype status in women with the FSHR Ser680Asn Ser/Ser genotype is more effective than routine management in terms of - the mean number of follicles - the mean number of embryos - the rate of poor responders - the rate of women with cycle cancellations, and v) the clinical pregnancy rates. Eligible women will be randomized to a stimulation protocol characterised by a longer duration and increased dosage of FSH stimulation (group A) or a standard stimulation protocol (group B).
NCT01075815 A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age Terminated Merck, S.L., Spain Phase 2 2008-11-01 This is a multicentric, open, randomized, comparative trial aimed to assess the influence of recombinant luteinizing hormone (r-LH) supplementation during controlled ovarian stimulation (COS) in advanced reproductive age in terms of improved embryo competence which allows to transfer less embryos to avoid high grade multiple pregnancy without reducing the pregnancy rate.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lutropin Alfa

Condition Name

Condition Name for Lutropin Alfa
Intervention Trials
Infertility 4
Infertility, Female 3
Ovulation Induction 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lutropin Alfa
Intervention Trials
Infertility 8
Infertility, Female 3
Hypogonadism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lutropin Alfa

Trials by Country

Trials by Country for Lutropin Alfa
Location Trials
Spain 4
Russian Federation 2
United States 1
Germany 1
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lutropin Alfa
Location Trials
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lutropin Alfa

Clinical Trial Phase

Clinical Trial Phase for Lutropin Alfa
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lutropin Alfa
Clinical Trial Phase Trials
Completed 3
Terminated 3
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lutropin Alfa

Sponsor Name

Sponsor Name for Lutropin Alfa
Sponsor Trials
Merck KGaA 5
Merck, S.L., Spain 2
Medical University of Vienna 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lutropin Alfa
Sponsor Trials
Industry 8
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Medtronic
McKesson
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.